nach oben

World Journal of Urology

Erschienen in:

22.04.2019 | Original Article

The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis

verfasst von: Xueming Lin, Tuo Deng, Shulin Wu, Sharron X. Lin, Dongwen Wang, Chin-Lee Wu

Erschienen in: World Journal of Urology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Urothelial carcinoma with squamous differentiation (UCSD) is the most common histologic variant in bladder cancer (BCa). Previously, some studies have linked the presence of UCSD with the risk of worse survival outcomes in BCa patients. However, such association is still controversial. In this study, we performed a meta-analysis to clarify the clinicopathological characteristics and to further investigate the prognostic value of UCSD in BCa.

Methods

A systematic literature search was performed in electronic databases including PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang Data until October 2018. Subgroup analyses were performed according to different treatments and study outcomes.

Results

Total of 13,284 patients were enrolled in 19 studies which were included in this meta-analysis. The percentage of female patients with UCSD was significantly higher than those with pure urothelial carcinoma. UCSD was correlated with tumor stage T3/T4, tumor grade 3, positive surgical margin, and lymph node involvement. Moreover, the recurrence rate was higher in patients with UCSD after surgery. UCSD was associated with poorer disease-free survival (DFS). No significant difference of cancer-specific survival (CSS) or overall survival (OS) was found on multivariable analysis between the two groups.

Conclusions

Our study demonstrated that UCSD in BCa was associated not only with unfavorable clinicopathological features, but also with high risk of recurrence and poorer prognosis for DFS. However, UCSD is not independently significant for CSS and OS. Well-designed randomized study with larger sample size is warranted to verify the findings and to further explore the role of UCSD in BCa.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics 2018. CA Cancer J Clin 68(1):7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Frazier HA, Robertson JE, Dodge RK, Paulson DF (1993) The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 71(12):3993–4001. https://doi.org/10.1002/1097-0142(19930615)71:12%3c3993:aid-cncr2820711233%3e3.0.co;2-y CrossRefPubMed

Thrasher JB, Frazier HA, Robertson JE, Dodge RK, Paulson DF (1994) Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 73(6):1708–1715. https://doi.org/10.1002/1097-0142(19940315)73:6%3c1708:aid-cncr2820730626%3e3.0.co;2-j CrossRefPubMed

Chen C, Hu L, Chen Y, Hou J (2017) The prognostic value of histological subtype in patients with metastatic bladder cancer. Oncotarget 8(17):28408–28417. https://doi.org/10.18632/oncotarget.16083 CrossRefPubMedPubMedCentral

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE (2016) The 2016 WHO Classification of tumours of the urinary system and male genital organs-Part B: prostate and bladder tumours. Eur Urol 70(1):106–119. https://doi.org/10.1016/j.eururo.2016.02.028 CrossRefPubMed

Shapur NK, Katz R, Pode D, Shapiro A, Yutkin V, Pizov G, Appelbaum L, Zorn KC, Duvdevani M, Landau EH, Gofrit ON (2011) Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors 3(2):e22. https://doi.org/10.4081/rt.2011.e22 CrossRefPubMedPubMedCentral

Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, Shariat SF (2013) Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. European journal of cancer (Oxford, England: 1990) 49 (8):1889-1897. https://doi.org/10.1016/j.ejca.2013.02.001 CrossRef

Cai T, Tiscione D, Verze P, Pomara G, Racioppi M, Nesi G, Barbareschi M, Brausi M, Gacci M, Luciani LG, Liguori G, Gontero P, Campodonico F, Simonato A, Boddi V, Di Stasi SM, Colombo R, Serretta V, Carmignani G, Malossini G, Altieri V, Carini M, Terrone C, Bassi P, Montorsi F, Ficarra V, Selli C, Mirone V, Bartoletti R (2014) Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. Urology 84(5):1141–1146. https://doi.org/10.1016/j.urology.2014.06.032 CrossRefPubMed

10.

Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA (2017) Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy. Eur Urol 72(1):54–60. https://doi.org/10.1016/j.eururo.2016.12.002 CrossRefPubMed

11.

Moschini M, Dell'Oglio P, Luciano R, Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, Shariat SF, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A (2017) Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol 35(6):335–341. https://doi.org/10.1016/j.urolonc.2016.12.006 CrossRefPubMed

12.

Brimo F, Downes MR, Jamaspishvili T, Berman D, Barkan GA, Athanazio D, Abro S, Visram K, Yilmaz A, Solanki S, Hahn E, Siemens R, Kassouf W, Trpkov K (2018) Prognostic pathological factors in radical cystectomy after neoadjuvant chemotherapy. Histopathology 73(5):732–740. https://doi.org/10.1111/his.13654 CrossRefPubMed

13.

Ku JH, Yuk HD, Godoy G, Amiel GE, Lerner SP (2018) Prognostication in patients treated with radical cystectomy for urothelial bladder carcinoma: a new simplified model incorporating histological variants. Bladder Cancer 4(2):195–203. https://doi.org/10.3233/blc-170156 CrossRefPubMedPubMedCentral

14.

Moschini M, Shariat SF, Luciano R, D'Andrea D, Foerster B, Abufaraj M, Bandini M, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A (2017) Pure but not mixed histologic variants are associated with poor survival at radical cystectomy in bladder cancer patients. Clin Genitourin Cancer 15(4):e603–e607. https://doi.org/10.1016/j.clgc.2016.12.006 CrossRefPubMed

15.

Soave A, Schmidt S, Dahlem R, Minner S, Engel O, Kluth LA, John LM, Hansen J, Schmid M, Sauter G, Shariat SF, Fisch M, Rink M (2015) Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol 33 (1):21 e21-21 e29. https://doi.org/10.1016/j.urolonc.2014.10.013 CrossRef

16.

Hsieh MC, Sung MT, Chiang PH, Huang CH, Tang Y, Su YL (2015) The prognostic impact of histopathological variants in patients with advanced urothelial carcinoma. PloS One 10(6):e0129268. https://doi.org/10.1371/journal.pone.0129268 CrossRefPubMedPubMedCentral

17.

Gellert LL, Warrick J, Al-Ahmadie HA (2015) Urothelial carcinoma with squamous differentiation–the pathologists perspective. Urol Oncol 33(10):437–443. https://doi.org/10.1016/j.urolonc.2015.07.018 CrossRefPubMed

18.

Monn MF, Kaimakliotis HZ, Cary KC, Bihrle R, Pedrosa JA, Masterson TA, Foster RS, Gardner TA, Cheng L, Koch MO (2015) The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity? BJU Int 116(2):236–240. https://doi.org/10.1111/bju.12877 CrossRefPubMed

19.

Ehdaie B, Maschino A, Shariat SF, Rioja J, Hamilton RJ, Lowrance WT, Poon SA, Al-Ahmadie HA, Herr HW (2012) Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. j Urol 187(1):74–79. https://doi.org/10.1016/j.juro.2011.09.056 CrossRefPubMed

20.

Minato A, Fujimoto N, Kubo T (2017) Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder. Clin Genitourin Cancer 15(6):e1063–e1067. https://doi.org/10.1016/j.clgc.2017.07.008 CrossRefPubMed

21.

Li G, Yu J, Song H, Zhu S, Sun L, Shang Z, Niu Y (2017) Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival. BMC Cancer 17(1):530. https://doi.org/10.1186/s12885-017-3520-1 CrossRefPubMedPubMedCentral

22.

Yang DY, Monn MF, Kaimakliotis HZ, Cho JS, Cary KC, Pedrosa JA, Bihrle R, Cheng L, Koch MO (2015) Does squamous differentiation portend worse outcomes in urothelial bladder cancer. Urol Pract 2(6):335–342. https://doi.org/10.1016/j.urpr.2015.02.003 CrossRef

23.

Mitra AP, Bartsch CC, Bartsch G Jr, Miranda G, Skinner EC, Daneshmand S (2014) Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol 32(2):117–127. https://doi.org/10.1016/j.urolonc.2012.08.017 CrossRefPubMed

24.

Monn MF, Kaimakliotis HZ, Pedrosa JA, Cary KC, Bihrle R, Cheng L, Koch MO (2015) Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol Oncol 33(1):18 e15–18 e20. https://doi.org/10.1016/j.urolonc.2014.10.001 CrossRef

25.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed) 339:b2700. https://doi.org/10.1136/bmj.b2700 CrossRef

26.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605. https://doi.org/10.1007/s10654-010-9491-z CrossRefPubMed

27.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557 CrossRef

28.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed) 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629 CrossRef

29.

Liu Y, Bui MM, Xu B (2017) Urothelial carcinoma with squamous differentiation is associated with high tumor stage and pelvic lymph-node metastasis. Cancer Control 24(1):78–82. https://doi.org/10.1177/107327481702400113 CrossRefPubMed

30.

Gofrit ON, Yutkin V, Shapiro A, Pizov G, Zorn KC, Hidas G, Gielchinsky I, Duvdevani M, Landau EH, Pode D (2016) The response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer. Front Oncol 6:43. https://doi.org/10.3389/fonc.2016.00043 CrossRefPubMedPubMedCentral

31.

Izard JP, Siemens DR, Mackillop WJ, Wei X, Leveridge MJ, Berman DM, Peng Y, Booth CM (2015) Outcomes of squamous histology in bladder cancer: a population-based study. Urol Oncol 33(10):425 e427–413. https://doi.org/10.1016/j.urolonc.2015.06.011 CrossRef

32.

Gluck G, Hortopan M, Stanculeanu D, Chirita M, Stoica R, Sinescu I (2014) Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors. J Med Life 7(2):211–214PubMedPubMedCentral

33.

Antunes AA, Nesrallah LJ, Dall'Oglio MF, Maluf CE, Camara C, Leite KR, Srougi M (2007) The role of squamous differentiation in patients with transitional cell carcinoma of the bladder treated with radical cystectomy. Int Braz J Urol 33(3):339–345. https://doi.org/10.1590/s1677-55382007000300006(discussion 346) CrossRefPubMed

34.

Bai J (2015) Clinicopathologic analysis of urothelial carcinoma of bladder with squamous differentiation. Health Care Today 4:141

35.

Cao K, Yang R, Li X, Guo H (2015) The clinical characteristics of high-grade urothelial carcinoma with squamous differentiation. J Mod Urol 20(10):715–717. https://doi.org/10.3969/j.issn.1009-8291.2015.10.009 CrossRef

36.

Minato A, Noguchi H, Tomisaki I, Fukuda A, Kubo T, Nakayama T, Fujimoto N (2018) Clinical significance of squamous differentiation in urothelial carcinoma of the bladder. Cancer Control 25(1):1–8. https://doi.org/10.1177/1073274818800269 CrossRef

37.

Mansour A, Laymon M, Elsaadany MM, Mosbah A, Shaaban AA, Abol-enein H (2017) Impact of tumor histopathologic types on pattern of tumor recurrence after radical cystectomy for muscle invasive bladder cancer (MIBC). J Urol 197(4S):e778–e778. https://doi.org/10.1016/j.juro.2017.02.1810 CrossRef

38.

Simone G, Enein HA, Ferriero M, Papalia R, Mosbah A, Abdel-latif M, Abdelrahim M, Guaglianone S, Ghoneim M, Gallucci M (2012) Squamous cell carcinoma vs urothelial carcinoma vs urothelial carcinoma with squamous differentiation: disease free survival after radical cystectomy in patients with high grade disease. The Journal of urology 187(4S):e645–e646. https://doi.org/10.1016/j.juro.2012.02.1368 CrossRef

39.

Sefik E, Celik S, Basmaci I, Yarimoglu S, Bozkurt IH, Yonguc T, Gunlusoy B (2018) Effect of variant histology presence and squamous differentiation on oncological results and patient's survival after radical cystectomy. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 90 (3):172-175. https://doi.org/10.4081/aiua.2018.3.172

40.

Berdik C (2017) Unlocking bladder cancer. Nature 551(7679):S34–S35. https://doi.org/10.1038/551s34a CrossRefPubMed

41.

Zhang ZL, Dong P, Li YH, Liu ZW, Yao K, Han H, Qin ZK, Zhou FJ (2014) Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients. Chin J Cancer 33(3):165–171. https://doi.org/10.5732/cjc.012.10312 CrossRefPubMedPubMedCentral

42.

Moschini M, Luzzago S, Zaffuto E, Dell'Oglio P, Gandaglia G, Mattei A, Damiano R, Soria F, Klatte T, Shariat SF, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R (2017) The surgical management of patients with clinical stage T4 bladder cancer: a single institution experience. Eur J Surg Oncol 43(4):808–814. https://doi.org/10.1016/j.ejso.2016.08.024 CrossRefPubMed

43.

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (3):466-477; discussion 475-467. https://doi.org/10.1016/j.eururo.2005.12.031 CrossRefPubMed

44.

Kluth LA, Black PC, Bochner BH, Catto J, Lerner SP, Stenzl A, Sylvester R, Vickers AJ, Xylinas E, Shariat SF (2015) Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature. Eur Urol 68(2):238–253. https://doi.org/10.1016/j.eururo.2015.01.032 CrossRefPubMed

45.

Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, Shariat SF, Zlotta AR, Boorjian SA (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69(2):300–310. https://doi.org/10.1016/j.eururo.2015.08.037 CrossRefPubMed

46.

Scosyrev E, Noyes K, Feng C, Messing E (2009) Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115(1):68–74. https://doi.org/10.1002/cncr.23986 CrossRefPubMed

47.

Liberman D, Alasker A, Sun M, Ismail S, Lughezzani G, Jeldres C, Budaus L, Thuret R, Shariat SF, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI (2011) Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study. BJU Int 107(6):905–911. https://doi.org/10.1111/j.1464-410x.2010.09590.x CrossRefPubMed

48.

Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Shariat SF (2010) Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol 183(1):87–93. https://doi.org/10.1016/j.juro.2009.08.145 CrossRefPubMed

49.

May M, Bastian PJ, Brookman-May S, Fritsche HM, Tilki D, Otto W, Bolenz C, Gilfrich C, Trojan L, Herrmann E, Moritz R, Tiemann A, Muller SC, Ellinger J, Buchner A, Stief CG, Wieland WF, Hofner T, Hohenfellner M, Haferkamp A, Roigas J, Zacharias M, Nuhn P, Burger M (2013) Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol Oncol 31(7):1141–1147. https://doi.org/10.1016/j.urolonc.2011.09.011 CrossRefPubMed

50.

Mazzucchelli L, Bacchi M, Studer UE, Markwalder R, Sonntag RW, Kraft R (1994) Invasion depth is the most important prognostic factor for transitional-cell carcinoma in a prospective trial of radical cystectomy and adjuvant chemotherapy. Int J Cancer 57(1):15–20. https://doi.org/10.1002/ijc.2910570104 CrossRefPubMed

51.

Moschini M, Shariat SF, Abufaraj M, Soria F, Klatte T, Croce G, Mattei A, Damiano R, Salonia A, Montorsi F, Briganti A, Colombo R, Gallina A (2017) The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. Urol Oncol 35 (4):151 e117-151 e123. https://doi.org/10.1016/j.urolonc.2016.11.003 CrossRef

52.

Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Saad F, Bell D, Drachenberg D, Kassouf W (2014) Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World journal of urology 32(5):1295–1301. https://doi.org/10.1007/s00345-013-1207-z CrossRefPubMed

53.

Chen Q, Li L, Wang G, Hu J, Sun T, Fu B (2017) Do histological variants in urothelial carcinoma of the bladder portend poor prognosis? A systematic review and meta-analysis. Oncotarget 8(29):48263–48271. https://doi.org/10.18632/oncotarget.17593

54.

Li G, Hu J, Niu Y (2018) Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. Oncotarget 9(1):217–223. https://doi.org/10.18632/oncotarget.18563

55.

Xu H, Xie L, Liu X, Zhang Y, Shen Z, Chen T, Qiu X, Sha N, Xing C, Wu Z, Hu H, Wu C (2017) Impact of squamous and/or glandular differentiation on recurrence and progression following transurethral resection for non-muscle invasive urothelial carcinoma of bladder. Oncol Lett 14(3):3522–3528. https://doi.org/10.3892/ol.2017.6581 CrossRefPubMedPubMedCentral

56.

Li CE, Chien CS, Chuang YC, Chang YI, Tang HP, Kang CH (2016) Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. Int Urol Nephrol 48(6):993–999. https://doi.org/10.1007/s11255-016-1264-5 CrossRefPubMed

57.

Zargar-Shoshtari K, Sverrisson EF, Sharma P, Gupta S, Poch MA, Pow-Sang JM, Spiess PE, Sexton WJ (2016) Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial carcinoma of the bladder with squamous or glandular differentiation. Clin Genitourin Cancer 14(1):82–88. https://doi.org/10.1016/j.clgc.2015.08.006 CrossRefPubMed

58.

Honma I, Masumori N, Sato E, Takayanagi A, Takahashi A, Itoh N, Tamagawa M, Sato MA, Tsukamoto T (2004) Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology 64(4):744–748. https://doi.org/10.1016/j.urology.2004.05.003 CrossRefPubMed

59.

Vetterlein MW, Wankowicz SAM, Seisen T, Lander R, Loppenberg B, Chun FK, Menon M, Sun M, Barletta JA, Choueiri TK, Bellmunt J, Trinh QD, Preston MA (2017) Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer 123(22):4346–4355. https://doi.org/10.1002/cncr.30907 CrossRefPubMed

60.

Berg S, D'Andrea D, Vetterlein MW, Cole AP, Fletcher SA, Krimphove MJ, Marchese M, Lipsitz SR, Sonpavde G, Noldus J, Shariat SF, Kibel AS, Trinh QD, Mossanen M (2019) Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter? Cancer. https://doi.org/10.1002/cncr.31952 CrossRefPubMedPubMedCentral

61.

Buisan O, Orsola A, Oliveira M, Martinez R, Etxaniz O, Areal J, Ibarz L (2017) Role of inflammation in the perioperative management of urothelial bladder cancer with squamous-cell features: impact of neutrophil-to-lymphocyte ratio on outcomes and response to neoadjuvant chemotherapy. Clin Genitourin Cancer 15(4):e697–e706. https://doi.org/10.1016/j.clgc.2017.01.024 CrossRefPubMed

62.

Moschini M, Shariat SF, Freschi M, Soria F, D'Andrea D, Abufaraj M, Foerster B, Dell'Oglio P, Zaffuto E, Mattei A, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R (2017) Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. Urol Oncol 35 (8):528 e521-528 e525. https://doi.org/10.1016/j.urolonc.2017.03.024 CrossRef

Titel: The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis
verfasst von: Xueming Lin
Tuo Deng
Shulin Wu
Sharron X. Lin
Dongwen Wang
Chin-Lee Wu
Publikationsdatum: 22.04.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 2/2020
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02771-1

Neu im Fachgebiet Urologie

24.04.2024 | DGIM 2024 | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Sonographic twinkling artifact for diagnosis of acute ureteral calculus

Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond

A modified technique for intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease results in reduced procedural morbidity using a standardized hematoma classification rubric

Evolution of the surgical sealing patch TachoSil® in Peyronie’s disease reconstructive surgery: technique and contemporary literature review

Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection

In response to “Obstructive sleep apnea syndrome should always be screened in patients complaining of nocturia”. World J Urol. 2018

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie